Journal Summary - Discover more summaries and articles from M3 India

Journal Summaries

Oncology

Myeloproliferative Dz

High-sensitivity cardiac troponin T determines all-cause mortality in cancer patients: A single-centre cohort study

ESC Heart Failure | Aug 20, 2021 Myeloproliferative Dz

Risk of lymphohematologic malignancies in patients with chronic plaque psoriasis: A systematic review with meta-analysis

Journal of the American Academy of Dermatology | Aug 19, 2021 Myeloproliferative Dz

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): A multicentre, open-label, single-arm, phase 1 study

The Lancet | Aug 17, 2021 Myeloproliferative Dz

Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study

Cancer | Aug 04, 2021 Myeloproliferative Dz

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b/2 open-label study

The Lancet | Jul 28, 2021 Myeloproliferative Dz

Randomized, single-blind, multicenter phase II study of two doses of imetelstat in relapsed or refractory myelofibrosis

Journal of Clinical Oncology | Jun 24, 2021 Myeloproliferative Dz

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): A multicentre, open-label, randomised phase 3 trial

The Lancet | Jun 23, 2021 Myeloproliferative Dz

Carfilzomib-lenalidomide-dexamethasone-daratumumab combination therapy for newly diagnosed multiple myeloma

JAMA | Jun 23, 2021 Myeloproliferative Dz

Association of frailty with clinical outcomes in myelofibrosis: A retrospective cohort study

British Journal of Haematology | Jun 20, 2021 Myeloproliferative Dz

Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma

Genes, Chromosomes and Cancer | Jun 20, 2021 Myeloproliferative Dz

« Prev 1 2 3 4 5 … 19 Next »

High-sensitivity cardiac troponin T determines all-cause mortality in cancer patients: A single-centre cohort study

Risk of lymphohematologic malignancies in patients with chronic plaque psoriasis: A systematic review with meta-analysis

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): A multicentre, open-label, single-arm, phase 1 study

Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b/2 open-label study

Randomized, single-blind, multicenter phase II study of two doses of imetelstat in relapsed or refractory myelofibrosis

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): A multicentre, open-label, randomised phase 3 trial

Carfilzomib-lenalidomide-dexamethasone-daratumumab combination therapy for newly diagnosed multiple myeloma

Association of frailty with clinical outcomes in myelofibrosis: A retrospective cohort study

Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma

BRI or BMI: What is More Efficient?

Enhancing Conventional Diabetes Management with Lifestyle and Nutritional Interventions

These Popular Snacks Linked a Decline in Mental Health

Addressing Sleep Disorders with Integrative Solutions: From Pharmaceuticals to Natural Remedies

Anaesthetic Management in Obese Patients

High-sensitivity cardiac troponin T determines all-cause mortality in cancer patients: A single-centre cohort study

Risk of lymphohematologic malignancies in patients with chronic plaque psoriasis: A systematic review with meta-analysis

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): A multicentre, open-label, single-arm, phase 1 study

Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b/2 open-label study

Randomized, single-blind, multicenter phase II study of two doses of imetelstat in relapsed or refractory myelofibrosis

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): A multicentre, open-label, randomised phase 3 trial

Carfilzomib-lenalidomide-dexamethasone-daratumumab combination therapy for newly diagnosed multiple myeloma

Association of frailty with clinical outcomes in myelofibrosis: A retrospective cohort study

Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma

BRI or BMI: What is More Efficient?

Enhancing Conventional Diabetes Management with Lifestyle and Nutritional Interventions

These Popular Snacks Linked a Decline in Mental Health

Addressing Sleep Disorders with Integrative Solutions: From Pharmaceuticals to Natural Remedies

Anaesthetic Management in Obese Patients

Select Specialty

Select Topic